Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy

The reply letter has been put forth in response to the comment made by Karthyayani Priya Satish entitled “India and the COVID-19 Vaccine.” The comment was made in context to our published work “Exploring the covid-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Gaurav, Poduri, Ramarao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Coronavirus – Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009944/
https://www.ncbi.nlm.nih.gov/pubmed/35240913
http://dx.doi.org/10.1080/21645515.2022.2034458
_version_ 1784687374171635712
author Joshi, Gaurav
Poduri, Ramarao
author_facet Joshi, Gaurav
Poduri, Ramarao
author_sort Joshi, Gaurav
collection PubMed
description The reply letter has been put forth in response to the comment made by Karthyayani Priya Satish entitled “India and the COVID-19 Vaccine.” The comment was made in context to our published work “Exploring the covid-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?” The reply letter is concerned with the newer variant of SARS-CoV-2, i.e., Omicron and its impact on severity and vaccine efficacy. Though the variant is mild, as per the reports, the cases are rising at an unprecedented rate that may create havoc on humankind considering shortages of RT-PCR testing and prevailing unequal vaccine distribution and vaccine hesitancy.
format Online
Article
Text
id pubmed-9009944
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-90099442022-04-15 Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy Joshi, Gaurav Poduri, Ramarao Hum Vaccin Immunother Coronavirus – Letters The reply letter has been put forth in response to the comment made by Karthyayani Priya Satish entitled “India and the COVID-19 Vaccine.” The comment was made in context to our published work “Exploring the covid-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?” The reply letter is concerned with the newer variant of SARS-CoV-2, i.e., Omicron and its impact on severity and vaccine efficacy. Though the variant is mild, as per the reports, the cases are rising at an unprecedented rate that may create havoc on humankind considering shortages of RT-PCR testing and prevailing unequal vaccine distribution and vaccine hesitancy. Taylor & Francis 2022-03-03 /pmc/articles/PMC9009944/ /pubmed/35240913 http://dx.doi.org/10.1080/21645515.2022.2034458 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Coronavirus – Letters
Joshi, Gaurav
Poduri, Ramarao
Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy
title Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy
title_full Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy
title_fullStr Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy
title_full_unstemmed Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy
title_short Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy
title_sort omicron, a new sars-cov-2 variant: assessing the impact on severity and vaccines efficacy
topic Coronavirus – Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009944/
https://www.ncbi.nlm.nih.gov/pubmed/35240913
http://dx.doi.org/10.1080/21645515.2022.2034458
work_keys_str_mv AT joshigaurav omicronanewsarscov2variantassessingtheimpactonseverityandvaccinesefficacy
AT poduriramarao omicronanewsarscov2variantassessingtheimpactonseverityandvaccinesefficacy

Ejemplares similares